Matthew Henn is the Executive Vice President and head of Discovery & Microbiome R&D at Seres Therapeutics. He has more than 20 years of combined research experience in microbial ecology, genomics, and bioinformatics that spans both environmental and infectious disease applications. He has been involved in the discovery and clinical development of multiple microbiome therapeutics including SER-109, SER-287, and SER-262, and has authored over 60 peer-reviewed publications. His research has focused on microbial populations and the functional role of microbes in both environmental and human disease applications, and also the development of genomic and functional tools to study these populations. Prior to helping launch Seres in 2012, he was the Director of Viral Genomics and Assistant Director of the Genome Sequencing Center for Infectious Diseases at the Broad Institute of MIT and Harvard. He has served on various NIH working groups on antimicrobial resistance and microbiome research, as a scientific advisor for the National Institutes of Health’s Viral Pathogen Bioinformatics Resource Center, and as an ad-hoc reviewer and editor of various peer-reviewed journals. He currently serves on the scientific advisory boards of the Forsyth Institute and Growcentia, Inc, an agricultural microbiome company. Dr. Henn earned his Ph.D. in ecosystem sciences from the University of California at Berkeley, where he was a NASA Earth Systems Sciences Fellow, and trained as a NSF Postdoctoral Fellow in microbiology at Duke University.